Skip to main content
SpringerLink
Log in

Outpatient Management and Long-Term Complications in Heart Transplantation

  • Chapter
  • First Online:
Clinical Guide to Heart Transplantation

Abstract

Outpatient management after heart transplantation requires longitudinal follow up to monitor for potential complications. Frequent follow up is required post heart transplant to monitor for allograft rejection (Chap. 12) or potential infection (Chap. 11). The focus of this chapter is the diagnosis and management of additional potential long term complications including cardiac allograft vasculopathy, malignancy, hypertension, renal dysfunction, hyperlipidemia, endocrine and bone complications, gastrointestinal complications, heart rhythm disorders, and other cardiac structural problems.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation. 2008;117(16):2131–41.

    Article  PubMed  Google Scholar 

  2. Roig E, Almenar L, Crespo-Leiro M, et al. Heart transplantation using allografts from older donors: multicenter study results. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2015;34(6):790–6.

    Article  Google Scholar 

  3. Nagji AS, Hranjec T, Swenson BR, et al. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. Ann Thorac Surg. 2010;90(1):168–75.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Moseley EL, Atkinson C, Sharples LD, Wallwork J, Goddard MJ. Deposition of C4d and C3d in cardiac transplants: a factor in the development of coronary artery vasculopathy. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2010;29(4):417–23.

    Article  Google Scholar 

  5. Rose ML. De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2004;23(4):385–95.

    Article  Google Scholar 

  6. Vasilescu ER, Ho EK, de la Torre L, et al. Anti-HLA antibodies in heart transplantation. Transpl Immunol. 2004;12(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  7. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80(8):1019–25.

    Article  PubMed  Google Scholar 

  8. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2011;11(2):312–9.

    Article  CAS  Google Scholar 

  9. Yousufuddin M, Haji S, Starling RC, et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J. 2004;25(5):377–85.

    Article  CAS  PubMed  Google Scholar 

  10. Kauke T, Kaczmarek I, Dick A, et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2009;28(4):305–11.

    Article  Google Scholar 

  11. Qin L, Huang Q, Zhang H, et al. SOCS1 prevents graft arteriosclerosis by preserving endothelial cell function. J Am Coll Cardiol. 2014;63(1):21–9.

    Article  CAS  PubMed  Google Scholar 

  12. de Weger RA. Immune regulators regulated to prevent transplant reactions. J Am Coll Cardiol. 2014;63(1):30–2.

    Article  PubMed  Google Scholar 

  13. Orloff SL, Hwee YK, Kreklywich C, et al. Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naive recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2011;11(1):45–55.

    Article  CAS  Google Scholar 

  14. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation. 2007;84(11):1436–42.

    Article  CAS  PubMed  Google Scholar 

  15. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2010;29(7):717–27.

    Article  Google Scholar 

  16. Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report–2014; focus theme: retransplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014;33(10):996–1008.

    Article  Google Scholar 

  17. Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 1992;11(5):892–901.

    CAS  Google Scholar 

  18. Dipchand AI, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric heart transplantation report–2014; focus theme: retransplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014;33(10):985–95.

    Article  Google Scholar 

  19. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2006;6(6):1248–56.

    Article  CAS  Google Scholar 

  20. Gao SZ, Hunt SA, Schroeder JS, Alderman EL, Hill IR, Stinson EB. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol. 1996;28(3):673–9.

    Article  CAS  PubMed  Google Scholar 

  21. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45(9):1532–7.

    Article  PubMed  Google Scholar 

  22. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol. 2005;45(9):1538–42.

    Article  PubMed  Google Scholar 

  23. Spes CH, Klauss V, Mudra H, et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and intravascular ultrasound. Circulation. 1999;100(5):509–15.

    Article  CAS  PubMed  Google Scholar 

  24. Kawano J KM, Patel J, et al. Do abnormal regadenoson scans predict subsequent poor outcome? J Heart Lung Transplant. 2015;34(4):S49.

    Google Scholar 

  25. Kawano JPJ, Kittleson M, et al. Rubidium positron emission tomography and coronary flow reserve predicts graft function after heart transplant. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2015;34(4S):S48.

    Article  Google Scholar 

  26. Wever-Pinzon O, Romero J, Kelesidis I, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63(19):1992–2004.

    Article  PubMed  Google Scholar 

  27. Kobashigawa J. Coronary computed tomography angiography: is it time to replace the conventional coronary angiogram in heart transplant patients? J Am Coll Cardiol. 2014;63(19):2005–6.

    Article  PubMed  Google Scholar 

  28. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333(10):621–7.

    Article  CAS  PubMed  Google Scholar 

  29. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107(1):93–7.

    Article  CAS  PubMed  Google Scholar 

  30. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359(9312):1108–13.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang R, Haverich A, Struber M, Simon A, Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2008;27(6):603–9.

    Article  CAS  Google Scholar 

  32. Azarbal B, Cheng R, Vanichsarn C, et al. Induction therapy with antithymocyte globulin in patients undergoing cardiac transplantation is associated with decreased coronary plaque progression as assessed by intravascular ultrasound. Circ Heart Fail. 2016;9(1):c002252.

    Google Scholar 

  33. Kaczmarek I, Ertl B, Schmauss D, et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2006;25(5):550–6.

    Article  Google Scholar 

  34. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847–58.

    Article  CAS  PubMed  Google Scholar 

  35. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110(17):2694–700.

    Article  CAS  PubMed  Google Scholar 

  36. Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(5):1203–16.

    Article  CAS  Google Scholar 

  37. Kobashigawa JA, Pauly DF, Starling RC, et al. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart failure. 2013;1(5):389–99.

    Article  PubMed  Google Scholar 

  38. Andreassen AK, Andersson B, Gustafsson F, et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2014;14(8):1828–38.

    Article  CAS  Google Scholar 

  39. Oliven A, Shechter Y. Extracorporeal photopheresis: a review. Blood Rev. 2001;15(2):103–8.

    Article  CAS  PubMed  Google Scholar 

  40. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med. 1998;339(24):1744–51.

    Article  CAS  PubMed  Google Scholar 

  41. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2006;25(3):283–8.

    Article  CAS  Google Scholar 

  42. Reddy PR, Gulati A, Steen L, Sinacore J, Leya F, Heroux A. Outcomes of bare metal versus drug-eluting stents in allograft vasculopathy. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2008;27(11):1222–8.

    Article  Google Scholar 

  43. Azarbal B, Arbit B, Ramaraj R, et al. Clinical and angiographic outcomes with everolimus eluting stents for the treatment of cardiac allograft vasculopathy. J Interv Cardiol. 2014;27(1):73–9.

    Article  PubMed  Google Scholar 

  44. Halle 3rd AA, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 1995;26(1):120–8.

    Article  PubMed  Google Scholar 

  45. Musci M, Loebe M, Wellnhofer E, et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg. 1998;46(5):268–74.

    Article  CAS  PubMed  Google Scholar 

  46. Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery. 2001;130(4):660.

    Article  CAS  PubMed  Google Scholar 

  47. Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk amoung US solid organ transplant recipients. JAMA. 2011;306(17):1891–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor beta1 expression and promotes tumor progression. Transplantation. 2003;76(3):597.

    Article  CAS  PubMed  Google Scholar 

  49. Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, et al. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant. 2010;25(7):2089–98.

    Article  PubMed  Google Scholar 

  50. Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997–1002.

    Article  PubMed  Google Scholar 

  51. Patel J, Kittleson M, Siddiqui S, et al. Does switching to oroliferation signal inhibitors decrease the risk of developing subsequent malignancies in heart transplant patients? Circulation. 2015;132:A15858.

    Google Scholar 

  52. Chang DH, Kittleson MM, Kobashigawa JA. Immunosuppression following heart transplantation: prospects and challenges. Immunotherapy. 2014;6(2):181–94.

    Article  CAS  PubMed  Google Scholar 

  53. Hoorn EJ, Walsh SB, McCormick JA, et al. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol. 2012;25(3):269–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Erinc K, Yamani MH, Starling RC, et al. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2005;24(8):1033–8.

    Article  Google Scholar 

  55. Yabuno J, Patel J, Kittleson M, et al. Patients with autoimmune disease: not a contraindication for heart transplant. Circulation. 2015;132:A13688.

    Google Scholar 

  56. Shane E, Mancini D, Aaronson K, et al. Bome mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197.

    Article  CAS  PubMed  Google Scholar 

  57. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow up study. Lancet. 2001;357:342.

    Article  CAS  PubMed  Google Scholar 

  58. Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab. 1996;81:1740.

    CAS  PubMed  Google Scholar 

  59. Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004;350:767.

    Article  CAS  PubMed  Google Scholar 

  60. Vaseghi M, Boyle N, Kedia R, et al. Supraventricular tachycardia after orthotopic ccardiac transplant. J Am Coll Cardiol. 2008;51(23):2241–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heart Failure/Transplant Cardiologist, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

    David Chang MD

  2. Director, Advanced Heart Disease Section, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

    Jon Kobashigawa MD

  3. Director, Heart Transplant Program, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

    Jon Kobashigawa MD

  4. Cedars-Sinai Heart Institute, Los Angeles, CA, USA

    Minh Luu MA, MBBS (Research Associate)

Authors
  1. David Chang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jon Kobashigawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Minh Luu MA, MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Chang MD .

Editor information

Editors and Affiliations

  1. Director, Advanced Heart Disease Section, Cedars-Sinai Heart Institute, Los Angeles, California, USA

    Jon Kobashigawa

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Chang, D., Kobashigawa, J., Luu, M. (2017). Outpatient Management and Long-Term Complications in Heart Transplantation. In: Kobashigawa, J. (eds) Clinical Guide to Heart Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-43773-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43773-6_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43771-2

  • Online ISBN: 978-3-319-43773-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation